Sunday, October 22, 2017 7:18:17 PM
FXS id their baby right now and they plan to bring it to market all on their own. Phase 3 costing only 5+ mill or so..
Epilepsy update, now in advanced open label study where they are seeing close to 50% overall reduction in seizures. Trial was a failure at first but have worked out the kinks and many original patients remain on the program. Company has basically decided to move forward and plans on restructuring a new phase II study and focus it more on children. As the drug seems to have excellent response in younger brains.
Meeting with the FDA will be taking place before year end to discus restructuring of a phase 3 O/A to address secondary end points and focus the study on men.
ZYN001 update, still on target to release phase 1 data before year end. the company has taken time testing more dosage levels and time frames making phase 2 and 3 much easier to work with flexibility wise. Allowing for more options with dosing/endpoints.
Phase 2 enrollment will follow first half 2018.
Earnings and summary should be out 2nd week of Nov.
Estimated revenue on first year approval of zyn001 & zyn002 is approx 1.5+ billion dollars putting a non diluted target price of $115 a share.
Company currently has 78 mil in cash and private investors that will support phase 3 studies out to 2019!
Cheers. ????
Recent ZYNE News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 12:22:51 AM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 10/19/2023 08:48:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/12/2023 04:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:12:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:02:08 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/11/2023 01:27:41 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/11/2023 01:27:00 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 10/11/2023 12:56:22 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/11/2023 12:31:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 12:17:36 PM
- HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE • PR Newswire (US) • 10/11/2023 12:00:00 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 10/04/2023 09:29:21 PM
- Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions • GlobeNewswire Inc. • 10/04/2023 08:05:00 PM
- Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 • GlobeNewswire Inc. • 09/29/2023 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM